Semaglutide is a glucagon-like peptide-1 analogue (GLP-1) approved for once-weekly (OW) subcutaneous treatment of type 2 diabetes (Ozempic®). This randomised, double-blind, placebo-controlled, 13-week trial assessed the pharmacokinetics, safety and tolerability of OW semaglutide in healthy male and female Chinese subjects. A total of 36 subjects were randomised to 0.5 mg (n=12) or 1.0 mg (n=12) OW semaglutide, or corresponding volumes of placebo (n=12). The primary endpoint was steady-state semaglutide exposure (AUC0 168h [area under the curve over a dosing interval]). Semaglutide exposure at steady state (see Figure) was consistent with dose-proportionality. Treatment ratios (1.0 mg/0.5 mg) were: AUC0-168h: 1.99, and Cmax: 1.94. Accumulation was consistent with the half-life (∼1 week). In this trial, treatment with OW semaglutide was well tolerated, consistent with the GLP-1 class. The PK profile in Chinese subjects was consistent with previous trials. The most common adverse events were gastrointestinal events. NCT03288740.


A. Shi: None. P. Xie: None. L.L. Nielsen: None. T.V. Skjoeth: Employee; Self; Novo Nordisk A/S. X. He: None. S.P. Haugaard: Employee; Self; Novo Nordisk A/S.


Novo Nordisk A/S

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at